All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
In the past decade, tremendous progress has been made in the field of immunotherapy, especially in the field of T cell therapy. This method uses engineered T cells with artificial chimeric antigen receptors (CAR) as an example, which can recognize specific proteins expressed on the surface of tumor cells, resulting in rapid activation and killing of tumor cells. Although clinical success has been achieved in a few tumor types, the types of surface proteins that can be targeted by this technology are limited, which severely limits the development of CAR-T cells for multiple tumor types. Besides, the targeted surface proteins so far are also expressed on normal cells, leading to CAR-T-mediated killing of non-cancer cells and potentially life-threatening side effects related to the intensity of the subsequent immune response.
To solve the problem of the scope and selectivity of CAR-T, researchers are turning to a method of engineering T cells based on T cell receptors (TCR-T). The ability of TCR to selectively recognize target cells comes from its unique ability to recognize cell surface "antigens". These antigens can be used as selective identifiers for malignant cells, and more and more tumor-related antigens are being identified, enabling the engineering of a potent and selective TCR-T directed against cancer.
As the leading cell therapeutics biotech that provides cell therapy related services, Creative Biolabs masters the most advanced CAR/TCR technology. With state-of-art TCR development platforms and advanced technologies, Creative Biolabs is capable of offering a broad range of TCR-T early development services, including TCR engineered T cell biomarker identification and selection, design, construction, and analysis. Moreover, our one-stop TCR development services also provide you the preclinical test.
With high-affinity TCR technology, Creative Biolabs is capable of identifying the candidate target tumor antigen and the sequence of tumor-specific TCR to create tumor-specific T cells.
To discover novel antigens of TCRs from viral or human genome-wide libraries, our scientists developed an advanced T-Scan platform, a T cell-based, high-throughput screening approach to identify functional T cell-specific epitopes for studying T cell responses.
In our Tseeking™ platform, we have designed a new TCR reporter cell line cassette for T cell activation that can sensitively read the specificity of any number of T cell-activating receptors, including but not limited, to CAR-T and TCR-T, and their ligands.
Creative Biolabs provides a cutting-edge platform for Antibody-Coupled T Cell Receptor (ACTR) technology, offering universal engineered T cell therapies that can be combined with various tumor-targeting antibodies to treat a wide range of cancers.
Creative Biolabs offers a comprehensive range of services for the development of off-the-shelf gamma delta (γδ) T cell therapies, including isolation, activation, expansion, characterization, and engineering of Vδ1 and Vδ2 T cells, as well as custom γδ bispecific T-cell engagers for cancer treatment.
Creative Biolabs provides custom development services for tetravalent bispecific (TetraBi) T-cell engagers, leveraging their experienced team and advanced technology to create effective cancer therapies with lower immunogenicity, stronger binding affinity, and higher safety.
Use the resources in our library to help you understand your options and make critical decisions for your study.
TCR-T cell therapy is an emerging form of cancer immunotherapy that modifies T cells to recognize and attack cancer cells more effectively. T cells are genetically engineered to express high-affinity T-cell receptors (TCRs) that can bind to specific antigens on cancer cells, triggering immune responses to eliminate the tumors. While promising for treating myeloma, myeloid malignancies, and solid tumors, this therapy faces challenges including safety concerns, potential off-target effects, and the need for improved manufacturing processes. Ongoing clinical trials continue to refine TCR-T therapy, highlighting both its potential and the hurdles that must be overcome for widespread clinical application.
Bispecific T cell engagers are antibody molecules with two antigen-binding sites, allowing them to simultaneously bind to tumor-associated antigens (TAA) on tumor cells and CD3 molecules on T cells. This dual binding redirects T cells to the tumor cell surface, activating T cell proliferation and cytotoxicity to kill tumor cells. These engagers consist of two single-chain variable fragments (scFv) and have a smaller molecular weight than conventional antibodies. Their mechanism of action involves activating T cells via CD3 binding, recruiting T cells to tumor cells, and inducing apoptosis through the release of effector molecules. Despite advantages such as using endogenous T cells and targeting diverse tumor antigens, bispecific T cell engagers face challenges like short half-life, potential toxicity, and immunosuppressive tumor environments. Ongoing developments aim to optimize their specificity, pharmacokinetics, and reduce adverse effects to enhance their therapeutic potential.
Based on the significant roles of T cells in the immune system, many small-molecule drugs targeting T cells and T-cell based immunotherapies have been developed for the treatment of intractable diseases including autoimmune diseases and cancer. T cell-based immunotherapies mainly utilize the mechanisms of T cell-mediated immune responses and the effects of some other immune cells such as dendritic cells (DCs), natural killer (NK) cells, and macrophages.
Adoptive cell transfer (ACT) of engineered T cells is a cutting-edge therapeutic approach revolutionizing cancer treatment. This innovative method involves modifying T cells, a key component of the immune system, to enhance their ability to target and eliminate cancer cells. By introducing genetically engineered T cells into patients, researchers aim to bolster the immune response against cancer, offering a personalized and potentially curative treatment option. This groundbreaking technology holds promise for addressing various malignancies and represents a significant stride towards more effective and precise cancer therapies.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION